Carboplatin and α-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study
- 31 December 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (7), 946-950
- https://doi.org/10.1016/0959-8049(94)90120-1
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1991
- A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancerGynecologic Oncology, 1990
- Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- First-Line Chemotherapy with Intraperitoneal Cisplatin and Intravenous Cyclophosphamide in Ovarian CarcinomaAmerican Journal of Clinical Oncology, 1989
- Carboplatin: current status and future prospectsCancer Treatment Reviews, 1988
- Pharmacokinetics of carboplatin after intraperitoneal administrationCancer Chemotherapy and Pharmacology, 1988
- Phase I study and pharmacokinetics of intraperitoneal carboplatinCancer Treatment Reviews, 1985
- Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assayInternational Journal of Cancer, 1985
- Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamicsAmerican Journal of Roentgenology, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958